Announcements Trials

Browse Landscape

Phase

Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Hepatocellular 26 Neoplasms 7 Liver Neoplasms 7 Leukemia, Myeloid, Acute 6 Carcinoma, Renal Cell 5 Breast Neoplasms 5 Recurrence 3 Leukemia 3 Kidney Neoplasms 3 Glioblastoma 3 Carcinoma, Non-Small-Cell Lung 3 Brain Neoplasms 3 Sarcoma 2 Prostatic Neoplasms 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Myelodysplastic Syndromes 2 Multiple Myeloma 2 Melanoma 2 Leukemia, Myelomonocytic, Chronic 2 Gliosarcoma 2 Colorectal Neoplasms 2 Waldenstrom Macroglobulinemia 1 Uterine Cervical Neoplasms 1 Stomach Neoplasms 1 Sezary Syndrome 1 Rectal Neoplasms 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Neoplasms, Squamous Cell 1 Neoplasms, Plasma Cell 1

Interventions

Nivolumab 9 Ipilimumab 4 linrodostat 2 relatlimab 1 regorafenib 1 Tetanus Toxoid 1 Sorafenib 1 Paclitaxel 1 Oxaliplatin 1 N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide 1 Gemcitabine 1 Cyclophosphamide 1 Cisplatin 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Advanced Cancer × Sorafenib × Clear all

NCT00785226 2016-10-17

RDEA119 and Sorafenib Combination Dose Escalation Study

Bayer

Phase 1/2 Completed

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡